News | Coronavirus (COVID-19) | April 17, 2020

Regarding sensitivity, specificity, and clinical practice, CT should be reserved for evaluation of complications of COVID-19 pneumonia or for assessment if alternative diagnoses are suspected

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 According to the 10 authors from multiple institutions across the US who reviewed the most frequently cited studies on the subject: 'Test performance and management issues arise when inappropriate and potentially overreaching conclusions regarding the diagnostic performance of CT for COVID-19 pneumonia are based on low-quality studies with biased cohorts, confounding variables, and faulty design characteristics.

According to the 10 authors from multiple institutions across the US who reviewed the most frequently cited studies on the subject: 'Test performance and management issues arise when inappropriate and potentially overreaching conclusions regarding the diagnostic performance of CT for COVID-19 pneumonia are based on low-quality studies with biased cohorts, confounding variables, and faulty design characteristics. Image courtesy of American Journal of Roentgenology (AJR)


April 17, 2020 — To date, the radiology literature on coronavirus disease (COVID-19) pneumonia has consisted of limited retrospective studies that do not substantiate the use of computed tomography (CT) as a diagnostic test for COVID-19, according to an open-access Clinical Perspective article in the American Journal of Roentgenology (AJR).

"This is not to say these studies are not valuable," maintained lead investigator Constantine A. Raptis, M.D., of Washington University in Saint Louis. As Raptis, Travis S. Henry, M.D., of the University of California-San Francisco, and nine co-authors from six institutions across the United States noted of the most frequently cited studies on the subject, reporting the various CT features of COVID-19 pneumonia remains "an important first step" in helping radiologists identify patients who may have COVID-19 in the appropriate clinical environment.

"However," they continue, "test performance and management issues arise when inappropriate and potentially overreaching conclusions regarding the diagnostic performance of CT for COVID-19 pneumonia are based on low-quality studies with biased cohorts, confounding variables, and faulty design characteristics."

CT Sensitivity

Because misdiagnosing even a single patient (i.e., obtaining a false-negative finding) could result in large outbreaks among future contacts, understanding the potential effects of selection bias is important in determining sensitivity. As Raptis and colleagues explained, "if a study cohort contains patients who are more likely to have a true-positive finding and less likely to have a false-negative finding, sensitivity will be overestimated."

CT Specificity

The specificity and positive predictive value of a laboratory test — in the case of COVID-19, reverse transcription-polymerase chain reaction (RT-PCR) — are based on its ability to limit false-positive findings. Acknowledging false-positive RT-PCR results are possible, Raptis, Henry, et al. maintained they are often caused by contamination and are likely insignificant in the setting of assays for COVID-19. CT, on the other hand, does not test for singular features unique to the disease, and even those features most characteristic of COVID-19 pneumonia — peripheral, bilateral ground-glass opacities typically in the lower lobes — have been reported in a number of other conditions, both infectious and noninfectious.

CT in Clinical Practice

Finally, Raptis and colleagues addressed the hazards of wide deployment of CT: overuse of hospital resources, including the use of PPE already limited in availability but required to safely perform CT studies; clustering of affected and nonaffected patients in the radiology department, increasing the risk of disease transmission among imaging staff.

"At present," the authors of this AJR article concluded, "CT should be reserved for evaluation of complications of COVID-19 pneumonia or for assessment if alternative diagnoses are suspected."

Moderated by AJR Cardiopulmonary Imaging Section Editor Patrick M. Colletti, Constantine A. Raptis and Travis S. Henry served as speakers for a recent AJR Live Webinar exploring the radiography and CT findings associated with EVALI and COVID-19 — including the limitations of imaging in their diagnosis.

For more information: www.arrs.org


Related Content

News | Radiology Business

April 23, 2024 — A diverse writing group—lead by authors at the University of Toronto—have developed an approach for ...

Time April 23, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

April 17, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the ...

Time April 17, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Population Health

April 4, 2024 — A new study found increased coronary vessel wall thickness that was significantly associated with ...

Time April 04, 2024
arrow
News | Radiation Oncology

April 2, 2024 — In a 10-center study, microwave ablation offered progression free survival rates and fewer complications ...

Time April 02, 2024
arrow
News | Radiation Therapy

March 28, 2024 — RefleXion Medical, Inc., a therapeutic oncology company, and Limbus AI, Inc., a provider of software ...

Time March 28, 2024
arrow
News | ACR

March 21, 2024 — The Advanced Research Projects Agency for Health (ARPA-H) has appointed American College of Radiology ...

Time March 21, 2024
arrow
News | Breast Imaging

March 20, 2024 — IceCure Medical Ltd., developer of the ProSense System, a minimally-invasive cryoablation technology ...

Time March 20, 2024
arrow
Subscribe Now